Presently, Sarah Gordon-Wild holds the position of Partner at Hy. Duke & Son Ltd.
She is also on the board of Oxford Nanopore Technologies Plc, Redx Pharma Plc, Leweston School and Evox Therapeutics Ltd.
In her past career she was Managing Director at Lone Pine Capital (UK) Ltd.
She received an undergraduate degree from the University of Aberdeen and a graduate degree from Imperial College London.